SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Ox who wrote (3365)7/1/2014 7:57:00 AM
From: The Ox  Read Replies (1) of 8239
 
Shares of Agenus ( AGEN) are up 15% premarket on modest volume in response to its report of positive results in a 46-patient Phase 2 clinical trial evaluating the safety and efficacy of its Prophage autologous cancer vaccine in patients with newly-diagnosed glioblastoma multiforme (GBM). In the study, 50% of patients lived for two years. This is significant because most patients with GBM die within one year. Prophage patients demonstrated a median overall survival of ~24 months. 33% of patients remain alive at 24 months and continue to be followed for survival. Median progression-free survival was almost 18 months which is 2 - 3x longer than patients treated with radiation and temozolomide alone. 22% of patients were alive without progression at 24 months and continue to be followed for survival.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News